Login to Your Account

Evolva Raises EUR12M To Drive Molecular Evolution Platform

By Cormac Sheridan

Wednesday, August 18, 2004
Evolva SA raised €12 million in a Series A round to further develop its Watchmaker platform, which employs yeast artificial chromosomes and flow cytometry for the synthesis and selection of novel compounds. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription